OBJECTIVE: This study aimed to investigate the efficacy of modest financial incentives in increasing completion of an accelerated 3-dose hepatitis B virus (HBV) vaccination schedule (0, 7, 21days) among people who inject drugs (PWID). METHODS: Randomised controlled trial. Participants were randomly allocated to receive $30 Australian Dollars cash following receipt of vaccine doses two and three ('incentive condition'), or standard care ('control condition'). Serologically confirmed HBV-susceptible PWID. Two inner-city health services and a field study site in Sydney, Australia. The primary outcome was completion of the vaccination series. Additional assessments included self-reported demographic, drug use and treatment, and risk-taking histories. RESULTS: Compared to the control condition, significantly more participants in the incentive condition received all three vaccine doses, under intention-to-treat analyses (n=139; 87% versus 66%; p=.004); and within the specified window periods under per protocol analyses (n=107 received three vaccine doses; 92% versus 67%; p=.001). Multivariate analysis indicated that the incentive condition and longer injecting histories significantly increased the likelihood of series completion. Aboriginal/Torres Strait Islanders were significantly less likely to complete the series. CONCLUSIONS: Modest financial incentives, per-dose, increased adherence to the accelerated HBV vaccination schedule among PWID. Results have implications for increasing HBV and, potentially, other vaccine-preventable infections, among PWID.
RCT Entities:
OBJECTIVE: This study aimed to investigate the efficacy of modest financial incentives in increasing completion of an accelerated 3-dose hepatitis B virus (HBV) vaccination schedule (0, 7, 21days) among people who inject drugs (PWID). METHODS: Randomised controlled trial. Participants were randomly allocated to receive $30 Australian Dollars cash following receipt of vaccine doses two and three ('incentive condition'), or standard care ('control condition'). Serologically confirmed HBV-susceptible PWID. Two inner-city health services and a field study site in Sydney, Australia. The primary outcome was completion of the vaccination series. Additional assessments included self-reported demographic, drug use and treatment, and risk-taking histories. RESULTS: Compared to the control condition, significantly more participants in the incentive condition received all three vaccine doses, under intention-to-treat analyses (n=139; 87% versus 66%; p=.004); and within the specified window periods under per protocol analyses (n=107 received three vaccine doses; 92% versus 67%; p=.001). Multivariate analysis indicated that the incentive condition and longer injecting histories significantly increased the likelihood of series completion. Aboriginal/Torres Strait Islanders were significantly less likely to complete the series. CONCLUSIONS: Modest financial incentives, per-dose, increased adherence to the accelerated HBV vaccination schedule among PWID. Results have implications for increasing HBV and, potentially, other vaccine-preventable infections, among PWID.
Authors: Evan S Herrmann; Alexis K Matusiewicz; Maxine L Stitzer; Stephen T Higgins; Stacey C Sigmon; Sarah H Heil Journal: J Subst Abuse Treat Date: 2016-06-24
Authors: Priya Wadhera; Jennifer L Evans; Ellen Stein; Monica Gandhi; Marie-Claude Couture; Neth Sansothy; Keo Sichan; Lisa Maher; John Kaldor; Kimberly Page Journal: Int J STD AIDS Date: 2014-12-12 Impact factor: 1.359
Authors: Camille C Cioffi; Derek Kosty; Christopher G Capron; Hannah F Tavalire; Robert C Barnes; Anne Marie Mauricio Journal: Public Health Rep Date: 2022-03-03 Impact factor: 3.117
Authors: C Brouard; J Pillonel; P Sogni; A Chollet; J V Lazarus; X Pascal; F Barin; M Jauffret-Roustide Journal: Epidemiol Infect Date: 2017-01-19 Impact factor: 4.434
Authors: Jack Stone; Natasha K Martin; Matthew Hickman; Margaret Hellard; Nick Scott; Emma McBryde; Heidi Drummer; Peter Vickerman Journal: PLoS One Date: 2016-05-25 Impact factor: 3.240